111 related articles for article (PubMed ID: 38142321)
1. Colorectal Cancer Screening in the Elderly: Does Increased Prevalence Necessitate Tighter Surveillance.
Suki M; Abu-Baker F; Beshara A; Ovadia B; Gal O; Kopelman Y
Isr Med Assoc J; 2023 Dec; 25(12):815-818. PubMed ID: 38142321
[TBL] [Abstract][Full Text] [Related]
2. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
3. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
4. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
5. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
6. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
7. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
9. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
[TBL] [Abstract][Full Text] [Related]
10. Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study.
Kubisch CH; Crispin A; Mansmann U; Göke B; Kolligs FT
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1612-1618.e3. PubMed ID: 27085763
[TBL] [Abstract][Full Text] [Related]
11. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
12. A direct comparison of the prevalence of advanced adenoma and cancer between surveillance and screening colonoscopies.
Crispin A; Mansmann U; Munte A; Op den Winkel M; Göke B; Kolligs FT
Digestion; 2013; 87(3):170-5. PubMed ID: 23635429
[TBL] [Abstract][Full Text] [Related]
13. Older age, symptoms, or anemia: Which factors increase colorectal cancer risk with a positive fecal immunochemical test?
Hamarneh Z; Symonds EL; Kholmurodova F; Cock C
J Gastroenterol Hepatol; 2020 Jun; 35(6):1002-1008. PubMed ID: 31606908
[TBL] [Abstract][Full Text] [Related]
14. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
Almansoori A; Alzaabi M; Alketbi L
BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
[TBL] [Abstract][Full Text] [Related]
15. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
[TBL] [Abstract][Full Text] [Related]
17. Physician-office vs home uptake of colorectal cancer screening using FOBT/FIT among screening-eligible US adults.
Chido-Amajuoyi OG; Sharma A; Talluri R; Tami-Maury I; Shete S
Cancer Med; 2019 Dec; 8(17):7408-7418. PubMed ID: 31637870
[TBL] [Abstract][Full Text] [Related]
18. Colorectal neoplasia prevalence in a predominantly Hispanic community: Results from a colorectal cancer screening program in Texas.
Willauer AN; Zuckerman MJ; Alomari A; Alvarado LA; Salaiz R; Casner N; Dwivedi AK; Shokar NK
Am J Med Sci; 2022 Oct; 364(4):394-403. PubMed ID: 35398033
[TBL] [Abstract][Full Text] [Related]
19. Screening Women Aged 50-59 for CRC Using Fecal Occult Blood Test Produces Outcomes Similar to Men Undergoing Screening Colonoscopy.
Mooers HM; Holub JL; Lieberman DA
Dig Dis Sci; 2018 Oct; 63(10):2780-2785. PubMed ID: 29948570
[TBL] [Abstract][Full Text] [Related]
20. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
